Els Torreele
Dados Biográficos
| ID | 6066656 |
|---|---|
| NOME | Els Torreele |
| PRENOMES | Els |
| SOBRENOME | Torreele |
| ASSINATURA | TORREELE E |
| AFILIAÇÕES | University College London |
| ORCID | 0000-0002-2566-3770 |
| VERIFICADO | Sim |
| TOTAL DE OBRAS | 10 |
| TOTAL DE CITAÇÕES | 6 |
| TOTAL COMO AUTOR | 10 |
| TOTAL COMO EDITOR | 0 |
| PRIMEIRO ANO DE PUBLICAÇÃO | 2002 |
| ANO MAIS RECENTE DE PUBLICAÇÃO | 2024 |
| ÍNDICE H | 1 |
The priority review voucher
WHAT IS ALREADY KNOWN ON THIS TOPIC The US Food and Drug Administration (FDA) Priority Review Voucher (PRV) is one of a set of push-and-pull mechanisms to incentivise investments into medical innovation for otherwise neglected, non-profitable diseases for pharmaceutical companies and investors, but its effectiveness has been questioned
Shaping the future of global access to safe, effective, appropriate and quality health products
status: Published
Mpox
Health equity requires transformational change
The Covid-19 vaccine market concentration and hoarding that left many Global South countries unable to access vaccines in a timely manner have led to calls to expand and decentralize manufacturing capacity as a critical element towards more equitable access to vaccines globally Multiple initiatives are underway to build manufacturing infrastructure in low-and middle income countries (LMICs). However, without proper attention to who owns and contr…
How to ensure a needs-driven and community-centred vaccination strategy for Covid-19 in Africa
Objective To characterise the clinical features of children and young people admitted to hospital with laboratory-confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in the UK, and explore factors associated with admission to critical care, mortality, and development of multisystem inflammatory syndrome in children and adolescents temporarily related to covid-19 (MIS-C). Design Prospective observational cohort study w…
Can we do for other essential medicines what we are doing for the Covid-19 vaccine
box By the beginning of 2021 the world welcomed encouraging news on several candidate vaccines for COVID-19. Pfizer-BioNTech, Moderna, Oxford/AstraZeneca and the Chinese BBIBP-CorV vaccines are already rolled out in some high-income countries, and other vaccines may follow. While in low-income and middle-income countries (LMICs) access is lagging, there are several vaccines with significant potential for fighting the pandemic in those LMICs that …
Engaging Human Rights in the Response to the Evolving Zika Virus Epidemic
In late 2015, an increase in the number of infants born with microcephaly in poor communities in northeast Brazil prompted investigation of antenatal Zika infection as the cause. Zika now circulates in 69 countries, and has affected pregnancies of women in 29 countries. Public health officials, policymakers, and international organizations are considering interventions to address health consequences of the Zika epidemic. To date, public health re…
Global health security
The Ebola virus disease outbreak in West Africa was unprecedented in both its scale and impact. Out of this human calamity has come renewed attention to global health security--its definition, meaning, and the practical implications for programmes and policy. For example, how does a government begin to strengthen its core public health capacities, as demanded by the International Health Regulations? What counts as a global health security concern…
No drugs in an age of plenty
Although patients with HIV/AIDS have benefited significantly frommedical and scientific innovation over the past twenty-five years, new treatments aredeveloped mainly in industrialised countries and for rich patients. The benefits of theselife-changing medical advances have yet to filter down to poorer countries. As for the rest,few new medicines exist to tackle infectious diseases that continue to kill millions yetwhich in some cases are hardly …
Drug development for neglected diseases
Engaging Human Rights in the Response to the Evolving Zika Virus Epidemic
In late 2015, an increase in the number of infants born with microcephaly in poor communities in northeast Brazil prompted investigation of antenatal Zika infection as the cause. Zika now circulates in 69 countries, and has affected pregnancies of women in 29 countries. Public health officials, policymakers, and international organizations are considering interventions to address health consequences of the Zika epidemic. To date, public health re…
Drug development for neglected diseases
No drugs in an age of plenty
Although patients with HIV/AIDS have benefited significantly frommedical and scientific innovation over the past twenty-five years, new treatments aredeveloped mainly in industrialised countries and for rich patients. The benefits of theselife-changing medical advances have yet to filter down to poorer countries. As for the rest,few new medicines exist to tackle infectious diseases that continue to kill millions yetwhich in some cases are hardly …
Global health security
The Ebola virus disease outbreak in West Africa was unprecedented in both its scale and impact. Out of this human calamity has come renewed attention to global health security--its definition, meaning, and the practical implications for programmes and policy. For example, how does a government begin to strengthen its core public health capacities, as demanded by the International Health Regulations? What counts as a global health security concern…
Engaging Human Rights in the Response to the Evolving Zika Virus Epidemic
In late 2015, an increase in the number of infants born with microcephaly in poor communities in northeast Brazil prompted investigation of antenatal Zika infection as the cause. Zika now circulates in 69 countries, and has affected pregnancies of women in 29 countries. Public health officials, policymakers, and international organizations are considering interventions to address health consequences of the Zika epidemic. To date, public health re…
How to ensure a needs-driven and community-centred vaccination strategy for Covid-19 in Africa
Objective To characterise the clinical features of children and young people admitted to hospital with laboratory-confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in the UK, and explore factors associated with admission to critical care, mortality, and development of multisystem inflammatory syndrome in children and adolescents temporarily related to covid-19 (MIS-C). Design Prospective observational cohort study w…
Can we do for other essential medicines what we are doing for the Covid-19 vaccine
box By the beginning of 2021 the world welcomed encouraging news on several candidate vaccines for COVID-19. Pfizer-BioNTech, Moderna, Oxford/AstraZeneca and the Chinese BBIBP-CorV vaccines are already rolled out in some high-income countries, and other vaccines may follow. While in low-income and middle-income countries (LMICs) access is lagging, there are several vaccines with significant potential for fighting the pandemic in those LMICs that …
The priority review voucher
WHAT IS ALREADY KNOWN ON THIS TOPIC The US Food and Drug Administration (FDA) Priority Review Voucher (PRV) is one of a set of push-and-pull mechanisms to incentivise investments into medical innovation for otherwise neglected, non-profitable diseases for pharmaceutical companies and investors, but its effectiveness has been questioned
Shaping the future of global access to safe, effective, appropriate and quality health products
status: Published
Mpox
Health equity requires transformational change
The Covid-19 vaccine market concentration and hoarding that left many Global South countries unable to access vaccines in a timely manner have led to calls to expand and decentralize manufacturing capacity as a critical element towards more equitable access to vaccines globally Multiple initiatives are underway to build manufacturing infrastructure in low-and middle income countries (LMICs). However, without proper attention to who owns and contr…
Medicine (7 obras) · Political science (7 obras) · Business (6 obras) · Economics (5 obras) · Economic growth (4 obras) · Public health (4 obras) · Biotechnology and Related Fields (3 obras) · Disease (3 obras) · Environmental health (3 obras) · Law (3 obras)